Piramal Pharma Q2/H1 FY27 Revenue Up 28%/23%, EBITDA Up 72% YoY
Piramal Pharma reported Q2FY27 consolidated revenue of ₹2,617 crore (up 28% YoY) and H1FY27 revenue of ₹4,887 crore (up 23% YoY). EBITDA surged 72% YoY to ₹385 crore in Q2 and ₹669 crore in H1. The company has upgraded its FY27 revenue growth outlook to 19-20% with improved profitability. Piramal Pharma will host an investor call on October 28, 2026.
The substantial increase in revenue and profitability, coupled with an upgraded future outlook, indicates a significant positive impact on the company's financial performance and investor confidence.
The company reported strong year-on-year growth in revenue and EBITDA, alongside significant margin expansion. The upgraded FY27 outlook further reinforces the positive sentiment.
Piramal Pharma Limited announced its standalone and consolidated financial results for the second quarter (Q2) and half year (H1) ended September 30, 2026.
Consolidated revenue from operations saw significant year-on-year growth, increasing by 28% to ₹2,617 crore in Q2FY27 and by 23% to ₹4,887 crore in H1FY27. This growth was broad-based, driven by strong performance across all three business segments: CDMO, CHG, and PCH. The CDMO business reported a 36% YoY revenue growth in Q2FY27 and 28% in H1FY27, while CHG grew by 32% and 24% respectively. PCH showed a 13% YoY growth in Q2FY27 and 14% in H1FY27.
Profitability also improved substantially, with consolidated EBITDA rising by 72% YoY in both Q2FY27 and H1FY27, reaching ₹385 crore and ₹669 crore, respectively. EBITDA margins expanded by over 350 basis points in both periods. The company reported a net profit after tax of ₹5 crore in Q2FY27, compared to a loss of ₹99 crore in the prior year, and a loss of ₹64 crore in H1FY27, an improvement from a loss of ₹181 crore in H1FY26.
Key business highlights include robust RFP activity and order inflows in the CDMO segment, with 22 new customers added in H1FY27. The company also upgraded its FY27 outlook, now expecting revenue growth of 19% to 20% with meaningfully higher profitability, driven by strong first-half performance and continued business momentum. The Bayer distribution agreement is set to expire in December 2026, with an expected low impact on FY27 guidance.
Piramal Pharma Limited will host an earnings conference call on October 28, 2026, from 10:00 AM to 10:45 AM IST to discuss these results.
What to do with a filing like this
Piramal Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.